Notice: Trying to get property 'slug' of non-object in /home/sgumdev/public_html/wp-content/themes/sgum_2016/single.php on line 44

The 12 Biotechs of Christmas: Five

By DrKSSMDPhD, December 19, 2016

(adsbygoogle = window.adsbygoogle || []).push({ google_ad_client: "ca-pub-0585312801691043", enable_page_level_ads: true });

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.]

Our fifth stock on this Christmas outing is unusual: a special situation. And I know what you’re thinking lately: KSS is overusing that term 10-bagger. As I see things, however, medically, clinically, event-wise, this stock too is possibly setting itself up for explosive yield within the next 12 months. Catalysts are coming by 3Q17. Interested? Do I have your attention?

For you to understand why this situation packs a wallop, or possibly will, however, I need to educate you a little.

Atrial fibrillation is a six-degrees-of-separation medical condition. Some of you reading have it, or have spouses who do, or children. You know someone who has it. Or it’s affected someone where you work or on your street in the subdivision. It’s a medical condition that falls under the huge rubric of cardiac “chronotropic incompetence.” Just like traditional Chinese medicine physicians, American medical students are trained to spend at least a full minute studiously taking the wrist pulse of each new patient to catch any hint of atrial fibrillation, and are taught to describe it as an “irregularly irregular” rhythm (as opposed to a “regularly irregular” rhythm such as one might have from add-on beats that occur at regular intervals). A beautiful young woman from Berlin, an exchange medical student, decried this as tosh over burgers with me, and explained that the German medical system’s term for atrial fibrillation translates “absolute arrhythmia’… rhythm, none-a’-tall. And there is lean eloquence in that. In 2015, five million Americans were walking around with tickers in atrial fibrillation (we’ll call it “afib” from here on out), and the number seems higher.

The problem with atrial fibrillation is that for most people, once you go into it, you stay in it. Afib means the cardiac upper chambers are purposelessly flailing, not organizing a pool of blood and kicking it downstairs to the ventricles. Blood in the left atrium can get “vectorless,” and congeal into clots…..and the clots love to go flying off into body circulation, such as into the brain, during apparent moments of reprieve (such as if ...

Sign Up for a Premium Membership

To view the rest of this article (and to have full access to the rest of our articles), sign up.
Already a member, log in.

Become a member

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info